Phaeohyphomycosis in China.

He, Yun; Zheng, Hai-Lin; Mei, Huan; Lv, Gui-Xia; Liu, Wei-da; Li, Xiao-Fang

He, Yun; Zheng, Hai-Lin; Mei, Huan; Lv, Gui-Xia; Liu, Wei-da; Li, Xiao-Fang.

Afiliación

He Y; Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College, Nanjing, China.
Zheng HL; Institute of Dermatology, Chinese Academy of Medical Science, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China.
Mei H; Skin Disease Prevention and Treatment Institute of Yixing, Yixing, China.
Lv GX; Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College, Nanjing, China.
Liu WD; Institute of Dermatology, Chinese Academy of Medical Science, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China.
Li XF; Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College, Nanjing, China.

Front Cell Infect Microbiol ; 12: 895329, 2022.

Article en En | MEDLINE | ID: mdl-35770068

Asunto(s)

COVID-19; Feohifomicosis; Antifúngicos/uso terapéutico; Hongos; Humanos; Feohifomicosis/diagnóstico; Feohifomicosis/tratamiento farmacológico; Feohifomicosis/epidemiología; Calidad de Vida; Voriconazol

Palabras clave

clinical features; diagnosis; drug sensitive; epidemiology; melanized fungi; phaeohyphomycosis; risk factors; treatment strategy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Feohifomicosis / COVID-19 Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Front Cell Infect Microbiol Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google